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Background: The effects of alpha-linolenic acid (ALA) on cardiovascular risk factors considerably vary between
published reports. Therefore, we investigated the effects of 12-week supplementation with flaxseed oil (FO), which
is a rich source of ALA, on cardiovascular risk factors such as serum small dense low-density lipoprotein (sd-LDL)
concentrations.
Methods: In a randomized, double blind, crossover study, 15 subjects ingested 10 g of FO or corn oil (CO), containing
5.49 g and 0.09 g of ALA, respectively, once daily with dinner. Blood samples were collected at 0, 4 and 12 weeks, and
were used for analysis of serum lipid, lipid-related proteins, serum fatty acids and serum sd-LDL cholesterol. Differences
during the test period were identified using a repeated-measures analysis of variance (ANOVA) for within-group effects.
Group differences were identified using paired t-test at each blood sampling time point.
Results: ALA and eicosapentaenoic acid concentrations were significantly higher in the FO period at 4 and 12 weeks
than in the CO period. No significant differences in docosahexaenoic acid concentrations were observed between two
periods, and cholesteryl ester transfer protein and apolipoprotein B concentrations were significantly lower in the FO
period than in the CO period at 12 weeks. FO supplementation was associated with a significant decrease in sd-LDL
concentrations at 4 and 12 weeks, and CO supplementation had no effect. Moreover, sd-LDL concentrations were
significantly lower in the FO period than in the CO period at 4 weeks. Among subjects with triglyceride (TG)
concentrations of >100 mg/dl, FO supplementation markedly reduced sd-LDL concentrations at 4 and 12 weeks
compared with baseline. Sd-LDL concentrations significantly differed between the periods at both 4 and 12 weeks.
Conclusion: This study indicates that the FO, which is a rich source of ALA, leads to lower sd-LDL cholesterol
concentrations.
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Metabolic syndrome is a cluster of inter-related plasma
lipid and lipoprotein abnormalities, including reduced
high-density lipoprotein (HDL) cholesterol, a predomin-
ance of small dense low-density lipoprotein (sd-LDL)
particles, and increased triglyceride (TG) concentration* Correspondence: okumurah@tokushima-u.ac.jp
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unless otherwise stated.[1]. These dyslipidemic features are associated with in-
creased risk of cardiovascular disease (CVD) [2].
Subclasses of LDL are characterised by variations in
density, size and chemical composition and are of clin-
ical importance [3]. Sd-LDL is a risk factor for the devel-
opment of coronary artery disease in Westerners [4,5]
and Japanese with relatively low LDL cholesterol con-
centrations [6,7]. In a recent study, sd-LDL cholesterol
was significantly associated with CVD development in a
Japanese population [8], indicating the importance of sd-
LDL cholesterol as a biomarker to predict CVD.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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n-3 fatty acids on CVD risk, and most of the health ben-
efits observed in these studies have been attributed to
the seafood n-3 fatty acids, eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) [9,10]. Compared with
seafood n-3 fatty acid, fewer studies have evaluated the
relationship between plant-derived n-3 fatty acid, alpha-
linolenic acid (ALA), and the risk of coronary heart dis-
ease and other CVD outcomes. Previous meta-analysis
showed that consumption of ALA might reduce heart
disease mortality [11], whereas other previous study
showed no significant cardiovascular benefit of ALA
supplementation [12,13]. Thus, the effects of ALA have
been inconsistent, and previous systematic review
pointed out some methodologic problems [12]. However,
recently there has been a steady increase in the number
of studies supporting specific health benefits of ALA
[14,15]. Furthermore, because seafood n-3 fatty acids
consumption is limited by availability, plant-based n-3
fatty acids containing ALA, which can be elongated and
desaturated to EPA and DHA [16], may be an important
dietary alternative source for the maintenance of optimal
EPA and DHA concentrations in plasma and cell mem-
branes. Therefore, characterization of the cardioprotec-
tive effects of ALA is of considerable importance with
regard to public health.
Therefore, the objective of this study was to elucidate
the effects of 12-week supplementation with flaxseed oil
(FO), which is a rich source of ALA, on cardiovascular
risk factors, including sd-LDL cholesterol.
Methods
Subjects
Twenty-six adult males with healthy and social lifestyles
were screened. Potential participants were screened by
medical history, physical examination, laboratory ana-
lysis, and daily intake of fish. Subjects with evidence of
infections, diabetes mellitus, renal, liver or inflammatory
disease were excluded. Subjects who regularly consumed
FO or perilla oil were also excluded. Among twenty-one
enrolled men, 1 withdrew before completion of the study
due to medication and 5 subjects were excluded for
non-compliance during the 12-week intervention. From
these participants, 15 subjects with a mean ± standard
error (SE) body mass index (BMI, kg/m2) of 25.1 ± 0.5
and a mean ± SE age of 44.5 ± 3.1 y completed the study.
Four subjects were smokers and 5 had received anti-
hypertensive drugs. Subject characteristics and labora-
tory data are presented in Table 1. According to TG
concentrations, 15 subjects were divided into two
groups: the TG < 100 mg/dl group (n = 5), and the TG >
100 mg/dl group (n = 10).
Informed consent was obtained from all participants
before the start of the study, which was approved by theethical committee of Tokushima University Hospital,
Tokushima, Japan. The study was performed in accord-
ance with the Helsinki Declaration.
Study design
In a randomized, double blind, crossover study, subjects
were given either FO or corn oil (CO) during two con-
secutive 12-week supplementation periods. The supple-
mentation periods were separated by a 8-week wash-out
period. The subjects were instructed to ingest 10 g of
FO or CO using the spoon provided, once daily with
dinner. Supplements of 10 g of FO and CO contained
5.49 and 0.09 g of ALA, respectively. Fatty acid composi-
tions of the two oils are presented in Table 2. The fatty
acid composition of the two oils was measured by gas–
liquid chromatography. To avoid oxidation, they were
instructed to put oil bottles in a box for blocking out
light and to store in the refrigerator.
Subjects were instructed to maintain their habitual diet
throughout the study to exclude influences of dietary
nutrients, and were asked to continue with their normal
daily activities. Subjects were also instructed to avoid in-
take of anti-inflammatory drugs, vitamins or other diet-
ary supplements throughout the intervention period.
Subjects recorded their daily activities and food intake
in a diary, and these life-style records were confirmed
during interviews every 2 weeks. Subjects returned used
oil bottles and were provided with oil supplements for
the following 2 weeks. Remaining volumes in returned
bottles were measured to assess compliance. All subjects
consumed more than 97% of the assigned oil quantity.
Subjects were visited at 0 (run-in period), 4 and
12 weeks to collect fasting blood samples, body weight,
and blood pressure measurement, and to hand in their
previous 3-day’s dietary records. Subjects were instructed
to eat and drink the same prescribed foods at 20.00 h
prior to scheduled visits. Fasting blood samples were
collected at 08.00 h after overnight fasting, and were
used for analysis of serum lipid, lipid-related proteins,
serum fatty acids and serum sd-LDL cholesterol. A
dietician calculated mean energy intake from each sub-
ject’s dietary records of the 3 days leading up to sched-
uled visits. These dietary records were analyzed using
computerized software (Excel Eiyou-kun version 4.0,
Kenpaku-sha, Tokyo, Japan) to determine caloric intake
and macronutrient content.
Analytic methods
Blood sample were centrifuged at 3000 rpm for 10 min
at 4°C and then separated into plasma or serum. Alpha-
tocopherol was measured using high-performance liquid
chromatography. Total cholesterol was determined by
the cholesterol dehydrogenase (UV-End) method. LDL-
cholesterol and HDL-cholesterol were determined by a
Table 1 Characteristics of the subjects (Mean values with their standard errors, 15 males)
All (n = 15) TG < 100 mg/dl (n = 5) TG > 100 mg/dl (n = 10)
Age (year) 44.5 ± 3.1 40.2 ± 5.3 46.7 ± 3.9
Body weight (kg) 71.2 ± 2.3 68.3 ± 4.1 72.7 ± 2.8
BMI (kg/m2) 25.1 ± 0.5 24.8 ± 0.8 25.2 ± 0.6
Abdominal circumference (cm) 88.0 ± 1.6 85.0 ± 2.6 89.5 ± 1.9
Systolic blood pressure (mmHg) 135.4 ± 3.8 128.2 ± 4.6 139.0 ± 4.9
Diastolic blood pressure (mmHg) 77.8 ± 2.9 70.8 ± 3.3 81.3 ± 3.7
Total cholesterol (mg/dl) 212.6 ± 6.2 220.8 ± 10.9 208.5 ± 7.6
LDL- cholesterol (mg/dl) 132.7 ± 6.1 146.0 ± 9.5 126.1 ± 7.2
HDL- cholesterol (mg/dl) 55.2 ± 2.5 57.6 ± 2.9 54.0 ± 3.5
non HDL- cholesterol (mg/dl) 157.4 ± 6.8 163.2 ± 11.9 154.5 ± 8.7
Small dense LDL-cholesterol (mg/dl) 41.1 ± 5.2 30.6 ± 9.5 46.3 ± 5.8
Triglyceride (mg/dl) 124.5 ± 11.8 79.8 ± 3.7 146.8 ± 12.5*
n-6/n-3 ratio 5.4 ± 0.6 5.6 ± 1.0 5.3 ± 0.7
Fasting plasma glucose (mg/dl) 104.1 ± 2.5 106.8 ± 3.7 102.7 ± 3.3
HbA1c (NGSP) (%) 5.4 ± 0.1 5.5 ± 0.1 5.4 ± 0.1
Fasting serum insulin (μU/ml) 7.9 ± 1.2 6.9 ± 2.1 8.4 ± 1.4
Aspartate aminotransferase (U/l) 21.3 ± 1.3 20.8 ± 1.9 21.5 ± 1.8
Alanine aminotransferase (U/l) 24.7 ± 2.3 24.0 ± 3.0 25.1 ± 3.1
γ-glutamyl transpeptidase (U/l) 41.7 ± 7.2 38.0 ± 8.0 43.6 ± 10.3
Creatinine (mg/dl) 0.8 ± 0.03 0.8 ± 0.04 0.8 ± 0.04
Urea nitrogen (mg/dl) 12.4 ± 0.4 11.7 ± 1.1 12.8 ± 0.4
Values are mean ± SE.
*Mean value was significantly different from that for TG < 100 mg/dl; p <0.05, Mann–Whitney U test.
Table 2 Fatty acid composition of corn oil and flaxseed oil
Corn oil Flaxseed oil
Fatty acid g/100 g
14:0 Myristic acid 0.1 0.1
16:0 Palmitic acid 12.0 5.2
16:1 Palmitoleic acid 0.2 0.1
17:0 Heptadecanoic acid 0.1 0.1
18:0 Stearic acid 2.0 3.8
18:1 Oleic acid 29.1 18.9
18:2n-6 Linoleic acid 54.5 16.2
18:3n-3 Alpha linolenic acid 0.9 54.9
20:0 Arachidic acid 0.5 0.2
20:1 Eicosenoic acid 0.3 0.2
20:2n-6 Eicosadienoic acid 0.0 0.1
22:0 Behenic acid 0.1 0.2
24:0 Lignoceric acid 0.2 0.0
n-6/n-3 ratio 60.6 0.3
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the difference between total and HDL cholesterol. TG
was determined by an enzyme method. The remnant like
particles (RLP) -cholesterol was determined by the im-
mune adherence method. Cholesterol ester transfer pro-
tein activity (CETP) was measured using a commercially
available ELISA kit (Daiichi-kagaku, Tokyo Japan). Apo-
lipoproteins (apo A-1, B, C-3 and E) were measured by
the turbidimetric immunoassay (TIA) system. Apo B-48
was measured by the chemiluminescent enzyme im-
munoassay (CLEIA). Serum fatty acids composition was
measured by gas–liquid chromatography. Briefly, total
lipids in the serum were extracted using the Folch pro-
cedure and fatty acids were then methylated with BF3/
methanol. Transesterified fatty acids was then analyzed
using a gas chromatograph (GC-17A; Shimadzu, Kyoto,
Japan) with a capillary column Omegawax 250 (Supelco,
Bellefonte, PA). Measurements of sd-LDL-cholesterol
were performed using sd-LDL-EX “SEIKEN” (Denka
Seiken, Tokyo, Japan).
Statistical analysis
Data are presented as the mean ± SE. Baseline physical
characteristic and laboratory data between the TG >
100 mg/dl group and the TG < 100 mg/dl group were
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the test period were identified using a repeated-measures
analysis of variance (ANOVA) and the Bonferroni method
for calculating 95% confidence interval (CI) after correct-
ing for multiple comparisons for within-group effects.
Group differences were identified using paired t-test at
each blood sampling time point. Differences were consid-
ered significant when P < 0.05. Statistical analyzes were
performed using SPSS for Windows, release 19.0 (SPSS,
Chicago, IL).
Results
Food and nutrient intake
Dietary intake in CO and FO periods is shown in Table 3.
At 0 week, no significant differences in total energy, pro-
tein, carbohydrate, fat, dietary fiber or alcohol intake
were observed between the periods.
In the FO period, total ALA intake was significantly
higher at 4 and 12 weeks than at 0 week. Total ALA in-
take at 4 and 12 weeks was significantly higher in the
FO period than in the CO period. In the CO period,
total linoleic acid (LA) intake was significantly higher at
4 and 12 weeks than at 0 week. Total LA intake at
12 weeks was significantly lower in the FO period than
in the CO period.
In the FO period, ratios of n-6/n-3 were significantly
lower at 4 and 12 weeks than at 0 week. In the CO
period, ratios of n-6/n-3 were significantly higher at 4
and 12 weeks than at 0 week. Ratios of n-6/n-3 at 4 and
12 weeks were significantly lower in the FO period than
in the CO period.
Alpha-tocopherol intakes at 12 weeks were signifi-
cantly lower in the FO period than in the CO period.Table 3 Dietary intakes of foods and nutrients in corn oil and
Corn oil period
0 week 4 week 12
Energy (kcal) 2054.3 ± 56.5 2266.3 ± 73.3 22
Protein (g) 69.2 ± 3.2 74.0 ± 3.4 76
Carbohydrate (g) 291.2 ± 11.2 304.3 ± 12.9 30
Fat (g) 51.9 ± 2.6 67.8 ± 3.7* 71
alpha-linolenic acid (mg) 925.0 ± 105.0 1929.0 ± 559.0 16
Eicosapentaenoic acid (mg) 250.0 ± 71.0 158.0 ± 48.0 15
Docosahexaenoic acid (mg) 484.0 ± 125.0 338.0 ± 76.0 28
Linoleic acid (mg) 6410.0 ± 592.0 13633.0 ± 927.0* 15
n-6/n-3 ratio 4.7 ± 0.7 7.7 ± 0.7* 8.3
Cholesterol (mg) 289.1 ± 31.0 298.7 ± 37.9 34
Dietary fiber (g) 8.3 ± 0.9 9.9 ± 0.6 10
alpha-tocopherol (mg) 4.4 ± 0.4 6.7 ± 0.5* 8.1
Alcohol (g) 16.5 ± 5.9 18.2 ± 5.4 17
Values are means ± SE, n = 15.
*; p <0.05 vs. baseline, repeated-measures ANOVA with Bonferroni correction, †; p <Anthropometric and laboratory data
Anthropometric and laboratory parameters from sub-
jects of CO and FO periods are shown in Table 4. No
significant differences in body weight were observed at
0 week, and no significant differences in alpha-
tocopherol concentrations were observed between the
two periods at the completion of the study.
Changes in serum lipids and lipid-related proteins in
CO and FO periods are shown in Table 5. No significant
differences in lipids and lipid-related proteins were ob-
served at 0 week. In the FO period, CETP concentra-
tions were significantly lower at 12 weeks than at 0 week
and were significantly lower than in the CO period at
12 weeks. Total cholesterol, LDL-, HDL-, non HDL-
cholesterol, apolipoprotein (Apo) A-1 and Apo B concen-
trations were significantly lower in the FO period than in
the CO period after 12 weeks. TG, RLP-cholesterol, apo
C-3, apo E and apo B48 concentrations didn’t change sig-
nificantly during the CO and FO periods.
Adverse events such as headache, fatigue, diarrhoea
and stomach fullness were observed in both periods but
were unrelated to the test diet. Moreover, no symptoms
or side-effects of test diets were noted during inquiries
about symptoms or during examinations.
Changes in serum fatty acid concentrations
Changes in serum fatty acid concentrations in CO and
FO periods are shown in Table 6. With the exception of
docosatetraenoic acid, no significant differences in
serum fatty acid composition were detected between the
two periods at 0 week. At 4 weeks, LA concentrations
were significantly increased in the CO period compared
with 0 week. Whereas in the FO period, concentrationsflaxseed oil periods
Flaxseed oil period
week 0 week 4 week 12 week
89.8 ± 76.2* 2146.3 ± 105.8 2349.2 ± 118.6 2261.4 ± 78.0
.3 ± 2.0 74.3 ± 5.2 75.6 ± 4.5 73.6 ± 3.6
2.5 ± 15.3 311.1 ± 16.7 315.5 ± 17.8 315.2 ± 15.9
.4 ± 3.2* 54.5 ± 4.8 70.8 ± 4.2* 64.1 ± 4.1
06.0 ± 136.0 1082.0 ± 161.0 6496.0 ± 216.0*† 6032.0 ± 140.0*†
3.0 ± 59.0 269.0 ± 83.0 153.0 ± 55.0 225.0 ± 75.0
8.0 ± 85.0 498.0 ± 140.0 329.0 ± 97.0 383.0 ± 109.0
675.0 ± 688.0* 7902.0 ± 850.0 10623.0 ± 1182.0 8106.0 ± 775.0†
± 0.8* 5.7 ± 0.9 1.5 ± 0.1*† 1.2 ± 0.1*†
4.8 ± 23.8 296.4 ± 40.3 319.7 ± 40.3 306.9 ± 44.2
.7 ± 0.6* 8.5 ± 0.8 9.8 ± 0.7 10.5 ± 1.1
± 0.5* 4.9 ± 0.7 5.9 ± 0.6 5.4 ± 0.5†
.0 ± 8.2 16.2 ± 6.6 20.1 ± 7.8 15.8 ± 5.4
0.05 vs. corn oil, paired t test.
Table 4 Anthropometric and laboratory parameters in corn oil and flaxseed oil periods
Corn oil period Flaxseed oil period
0 week 4 week 12 week 0 week 4 week 12 week
Body weight (kg) 72.2 ± 2.5 72.0 ± 2.5 72.4 ± 2.6 71.4 ± 2.4 71.9 ± 2.4 72.2 ± 2.5
Systolic blood pressure (mmHg) 132.4 ± 3.0 132.6 ± 3.3 126.1 ± 2.6 132.9 ± 4.3 134.8 ± 3.9 129.7 ± 3.5
Diastolic blood pressure (mmHg) 76.4 ± 2.6 77.0 ± 2.2 74.8 ± 2.4 77.6 ± 2.9 81.9 ± 3.2† 75.2 ± 3.0
Fasting plasma glucose (mg/dl) 102.5 ± 2.5 99.9 ± 2.5 102.5 ± 2.2 101.9 ± 2.2 102.2 ± 1.8 102.1 ± 1.9
HbA1c (%) 4.9 ± 0.1 4.9 ± 0.1 4.9 ± 0.1 5.0 ± 0.1 4.9 ± 0.1 5.0 ± 0.1
Fasting serum insulin (μU/ml) 8.5 ± 1.1 9.5 ± 1.4 9.1 ± 1.3 8.3 ± 1.3 9.1 ± 1.1 9.4 ± 1.5
Aspartate aminotransferase (U/l) 22.5 ± 2.0 21.4 ± 1.8 23.7 ± 1.6 21.0 ± 1.1 20.9 ± 1.1 23.8 ± 1.8
Alanine aminotransferase (U/l) 27.7 ± 3.7 26.1 ± 3.2 28.4 ± 3.1 23.4 ± 1.8 24.0 ± 2.6 26.3 ± 2.7
γ-glutamyl transpeptidase (U/l) 48.3 ± 10.8 47.4 ± 10.6 54.8 ± 14.5 45.3 ± 8.2 42.7 ± 8.7 50.7 ± 12.2
Creatinine (mg/dl) 0.8 ± 0.03 0.8 ± 0.06 0.8 ± 0.04 0.8 ± 0.03 0.8 ± 0.04 0.8 ± 0.04
Urea nitrogen (mg/dl) 12.6 ± 0.4 12.1 ± 0.8 11.9 ± 0.4 12.0 ± 0.5 11.1 ± 0.5 12.0 ± 0.6
alpha-tocopherol (μmol/l) 27.0 ± 1.5 27.6 ± 1.4 27.6 ± 1.4 26.7 ± 1.7 26.0 ± 1.6 26.3 ± 1.6
Values are means ± SE, n = 15.
†; p <0.05 vs. corn oil, paired t test.
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the CO period. Arachidonic acid concentrations were
significantly decreased at 12 weeks in both periods and
were significantly lower in the FO period than in the CO
period at 4 weeks.
ALA concentrations were significantly decreased at
12 weeks in the CO period, but were increased at 4 and
12 weeks in the FO period compared with 0 week and
were significantly higher than in the CO period at these
time points.
At 4 and 12 weeks, EPA concentrations were signifi-
cantly higher in the FO period than in the CO period.
However, no significant differences in docosapentaenoicTable 5 Changes in serum lipids and lipid-related proteins in
Corn oil period
0 week 4 week
Total cholesterol (mg/dl) 212.2 ± 7.7 204.9 ± 7.0
LDL-cholesterol (mg/dl) 135.3 ± 7.8 127.4 ± 7.3
HDL-cholesterol (mg/dl) 51.0 ± 2.3 51.8 ± 2.0
non HDL-cholesterol (mg/dl) 161.2 ± 8.0 153.1 ± 7.0
Triglyceride (mg/dl) 139.5 ± 13.7 141.3 ± 13.9
RLP-cholesterol (mg/dl) 5.1 ± 0.5 5.0 ± 0.4
CETP (μg/ml) 2.0 ± 0.1 2.0 ± 0.1
apoA-1 (mg/dl) 133.7 ± 5.7 133.7 ± 5.6
apoB (mg/dl) 106.6 ± 6.0 102.7 ± 5.1
apoC-3 (mg/dl) 10.5 ± 0.6 10.7 ± 0.7
apoE (mg/dl) 4.2 ± 0.2 4.2 ± 0.2
apoB48 (mg/dl) 3.8 ± 0.5 3.7 ± 0.5
Values are means ± SE, n = 15.
RLP-cholesterol; remnant like particles-cholesterol, CETP; cholesteryl ester transfer p
*; p <0.05 vs. baseline, repeated-measures ANOVA with Bonferroni correction, †; p <acid or DHA concentrations were detected between the
periods, and DHA concentrations significantly decreased
between 0 week and 12 weeks in both periods. Ratios of
n-6/n-3 significantly increased in the CO period at
12 weeks, but were significantly decreased in the FO
period at 4 and 12 weeks compared with 0 week. More-
over, n-6/n-3 ratios significantly differed between the pe-
riods at 4 and 12 weeks.
Serum sd-LDL concentrations
At 0 week, serum sd-LDL concentrations did not signifi-
cantly differ between the two periods (data not shown).
Changes in serum sd-LDL concentrations from 0 weekcorn oil and flaxseed oil periods
Flaxseed oil period
12 week 0 week 4 week 12 week
216.9 ± 7.7 210.1 ± 5.8 204.8 ± 6.7 202.3 ± 7.3†
137.9 ± 7.7 131.2 ± 6.1 126.3 ± 6.3 127.7 ± 7.2†
54.9 ± 3.0 53.3 ± 3.0 53.7 ± 2.7 49.2 ± 2.7†
162.0 ± 7.8 156.9 ± 6.6 151.1 ± 6.9 153.1 ± 7.0†
127.0 ± 17.0 126.1 ± 11.1 134.3 ± 15.2 112.9 ± 9.1
4.8 ± 0.6 4.4 ± 0.3 5.0 ± 0.5 4.1 ± 0.2
1.9 ± 0.1 1.9 ± 0.1 1.9 ± 0.1 1.8 ± 0.1*†
136.3 ± 5.1 135.1 ± 6.0 136.5 ± 5.9 129.1 ± 6.2†
106.7 ± 5.3 105.5 ± 4.9 101.4 ± 4.8 100.5 ± 5.0†
10.4 ± 0.7 9.9 ± 0.5 10.2 ± 0.6 9.6 ± 0.5
4.3 ± 0.3 4.3 ± 0.2 4.1 ± 0.3 3.9 ± 0.2
3.8 ± 0.5 3.0 ± 0.4 3.7 ± 0.5 3.6 ± 0.6
rotein.
0.05 vs. corn oil, paired t test.
Table 6 Changes in serum n-6 and n-3 fatty acids concentrations in corn oil and flaxseed oil periods
Corn oil period Flaxseed oil period
0 week 4 week 12 week 0 week 4 week 12 week
Linoleic acid (μg/ml) 907.2 ± 19.4 1004.7 ± 29.2* 908.8 ± 30.5 868.7 ± 23.3 909.6 ± 17.7† 792.0 ± 20.6†
γ-linolenic acid (μg/ml) 15.9 ± 1.6 15.8 ± 2.5 12.0 ± 1.5 12.7 ± 1.4 12.1 ± 1.4 10.5 ± 1.2
Eicosadienoic acid (μg/ml) 7.1 ± 0.3 7.0 ± 0.3 6.2 ± 0.3 6.5 ± 0.4 6.3 ± 0.4 5.3 ± 0.2*†
Dihomo-γ-linolenic acid (μg/ml) 44.4 ± 2.7 40.7 ± 2.7 36.0 ± 2.8* 39.4 ± 2.2 33.8 ± 2.3† 31.2 ± 2.0*
Arachidonic acid (μg/ml) 201.4 ± 10.7 187.3 ± 10.2 164.7 ± 7.6* 188.5 ± 10.1 172.7 ± 9.7† 163.5 ± 9.4*
Docosatetraenoic acid (μg/ml) 5.8 ± 0.5 5.3 ± 0.4 4.1 ± 0.2* 4.8 ± 0.3† 4.5 ± 0.4† 3.8 ± 0.3*
alpha-linolenic acid (μg/ml) 33.4 ± 2.4 30.7 ± 2.6 24.2 ± 1.8* 27.5 ± 2.5 92.8 ± 7.4*† 86.1 ± 8.7*†
Eicosapentaenoic acid (μg/ml) 77.5 ± 16.1 67.9 ± 10.8 49.6 ± 7.9* 77.7 ± 16.6 91.3 ± 15.6† 71.0 ± 10.7†
Docosapentaenoic acid (μg/ml) 24.9 ± 2.7 22.7 ± 2.2 17.9 ± 1.7* 22.5 ± 2.4 24.5 ± 1.9 19.6 ± 1.4
Docosahexaenoic acid (μg/ml) 138.1 ± 16.5 130.8 ± 14.7 107.4 ± 12.9* 132.9 ± 16.3 123.3 ± 12.9 102.8 ± 9.8*
n-6/n-3 ratio 5.1 ± 0.5 5.6 ± 0.5 6.5 ± 0.6* 5.3 ± 0.6 3.8 ± 0.3*† 3.9 ± 0.3*†
Values are means ± SE, n = 15.
*; p <0.05 vs. baseline, repeated-measures ANOVA with Bonferroni correction, †; p <0.05 vs. corn oil, paired t test.
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with 25.8% and 21.2% decreases in sd-LDL concentrations
at 4 and 12 weeks, respectively, although CO supplemen-
tation did not affect sd-LDL concentrations (Figure 1A).
At 4 weeks, sd-LDL concentrations were significantly
lower in the FO period than in the CO period.
Previous report showed that LDL particle size was in-
fluenced by TG concentrations [4]. To elucidate theFigure 1 Mean (±SE) percentage changes from baseline in serum sd-LDL
of >100 mg/dl (B), 5 subjects with TG concentrations of <100 mg/dl (C); open
period; *; p <0.05 vs. baseline, repeated-measures ANOVA with Bonferroni coreffect of baseline TG concentrations, we divided subjects
into two groups according to TG concentrations. Except
for TG concentrations, there were no significant differ-
ences between the TG > 100 mg/dl group and the TG <
100 mg/dl group at baseline (Table 1), although sdLDL
concentrations tended to be different (p = 0.055). Among
subjects with TG concentrations of >100 mg/dl, FO sup-
plementation led to 28.2% and 28.9% reductions in sd-concentrations. 15 subjects (A), 10 subjects with TG concentrations
circles indicate corn oil period, and closed circles indicate flaxseed oil
rection, †; p <0.05 vs. corn oil, paired t test.
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0 week, respectively, and sd-LDL concentrations signifi-
cantly differed between the periods at both 4 and
12 weeks (Figure 1B). However, among subjects with TG
concentration of <100 mg/dl, sd-LDL concentrations did
not differ between FO or CO supplementation at any
time point, but were significantly lower at 4 weeks in the
FO period compared with 0 week (Figure 1C).
Discussion
In the present study, we showed that FO supplementa-
tion markedly reduces serum sd-LDL concentrations,
particularly in subjects with TG concentrations of
>100 mg/dl. We also demonstrated that serum total
cholesterol, LDL-cholesterol, HDL-cholesterol, CETP,
Apo A-1 and Apo B concentrations were significantly
lower in the FO period than in the CO period after
12 weeks.
FO used in this study is a rich source of ALA, and pre-
vious meta-analyzes suggest that ALA consumption may
confer cardiovascular benefits, with a 10% decrease in
risk of CHD mortality for each 1 g/d increment of ALA
intake [14]. Furthermore, a recently published review
showed the current evidence for an association between
ALA and type 2 diabetes, and fracture risk, in addition
to CVD outcomes [15].
ALA is converted in the liver into EPA and DHA
[16,17], and n-6 fatty acids such as LA [18:2(n-6)] are
believed to decrease the conversion of ALA to longer-
chain n-3 PUFA by competing with ALA for binding to
the rate-limiting enzyme Δ6-desaturase [16,18]. Other
dietary factors such as polyunsaturated to saturated fat
ratios, relative consumption of EPA and trans fatty acids
and amounts and types of protein consumed have also
been shown to affect this conversion [19]. In the present
study, EPA concentrations were significantly higher after
4 and 12 weeks in the FO period than in the CO period,
but DHA concentrations did not differ between the pe-
riods. Reportedly, humans convert <5% of dietary ALA
to EPA or DHA [12,20]. In a previous randomised,
double-blind trial, 56 participants were given 3-g doses
of ALA/d from FO or olive oil placebo capsules. After
12 weeks, plasma EPA and docosapentaenoic acid (DPA)
concentrations were significantly increased among sub-
jects taking FO, whereas plasma DHA concentrations
did not change [21]. Thus, the present increases in
serum EPA concentrations may be clinically relevant.
However, in agreement with previous studies [22,23], in-
creased ALA intake failed to increase plasma phospholipid
DHA concentrations, suggesting that the conversion to
DHA is extremely low.
Previous study showed that non HDL-cholesterol
(LDL + IDL + VLDL cholesterol) was more potent pre-
dictors of CVD [24]. In this study, non HDL-cholesterolwas significantly lower in the FO period than in the CO
period after 12 weeks. Therefore, it indicates that the FO
supplementation could contribute to the improvement
of the lipid profile. On the other hand, HDL-cholesterol
concentrations were also significantly lower in the FO
period than in the CO period in this study. Other studies
also showed that HDL-cholesterol concentrations were
lower in the ALA group than in the LA group [25,26].
In another study, no significant differences in HDL-
cholesterol concentrations were found compared with
the ALA group and the LA group [27]. Therefore, the
effect of ALA on HDL-cholesterol concentrations is not
consistent.
Increased hepatic production and/or retarded clear-
ance from plasma of large VLDL result in increased pro-
duction of precursors of sdLDL particles. Thus far, seven
distinct LDL subspecies, which differ in their metabolic
behavior and pathological rules, have been identified
[28]. Plasma VLDL concentrations correlate with in-
creased density and decreased sizes of LDLs [29,30]. In
addition, LDL size and density are inversely correlated
with plasma concentrations of HDLs, particularly those
of the HDL2 subclass [31]. Sd-LDL particles are pro-
duced from intravascular processing of specific larger
VLDL precursors through a series of steps, including lip-
olysis [28]. A common lipoprotein profile, designated
the atherogenic lipoprotein phenotype, is characterised
by a predominance of sd-LDL particles. Multiple fea-
tures of this phenotype, including increased concentra-
tions of triglyceride rich lipoprotein remnants and IDLs,
and reduced concentrations of HDL and associated insu-
lin resistance, contribute to the risk of coronary heart
disease, particularly compared with individuals with pre-
dominantly larger LDLs. Reportedly, sd-LDL uptake by
arterial tissue is greater than for larger LDLs [32], sug-
gesting greater transendothelial transport of smaller par-
ticles. In addition, smaller LDL particles may have
decreased receptor-mediated uptake and increased pro-
teoglycan binding [33,34]. Several in vitro studies have
demonstrated that LDL subfractions differ in their sus-
ceptibility to oxidative stress, which is a significant
atherogenic factor [35,36]. Thus, increased concentra-
tions of sd-LDL subfractions may significantly contribute
to cardiovascular risk [37,38]. In the present study, sd-
LDL concentrations were markedly reduced in the FO
period, particularly in subjects with TG concentrations
of >100 mg/dl. Thus, ALA in FO may lower sd-LDL
cholesterols and contribute to reduce cardiovascular dis-
ease risk. Furthermore, although TG normal levels are
defined as <150 mg/dl, previous study showed that the
TG cutoff point that best distinguishes the two pheno-
types, which are characterized by a predominance of
large, buoyant LDL particles and sd-LDL particles, was
95 mg/dl in primarily healthy study sample [4]. Therefore,
Kawakami et al. Nutrition Journal  (2015) 14:39 Page 8 of 9we considered that the changes of serum sd-LDL concen-
trations, particularly in subjects with TG concentrations of
>100 mg/dl could be observed. However, we must take
into account the small subgroup sample size in this study.
Studying more subjects is clearly needed to determine the
effect of TG concentrations on the FO supplementation.
Previously, it was reported that n-3 fatty acids, such as
ALA, EPA and DHA, reduced secretion of apo B, in-
duced degradation of apo B [39,40] and decreased hep-
atic VLDL production [39]. There are two types of apo B
(apo B100 and apo B48). Apo B100 is produced in the
liver and apo B48 is produced in the proximal small in-
testine. In this study, we analyzed apo B and apo B48
concentrations. Apo B concentrations were significantly
lower in the FO period than in the CO period after
12 weeks, although apo B48 concentrations didn’t
change significantly during the CO and FO periods.
These results suggest that apo B, especially apo B100
concentrations, were significantly lower in the FO
period. Furthermore, a previous report showed that deg-
radation of CETP activity after EPA treatments may con-
tribute to lower sd-LDL concentrations [41]. In this
study, serum ALA and EPA concentrations were signifi-
cantly increased in the FO period compared with the
CO period, and CETP and Apo B concentrations were
significantly lower in the FO period than in the CO
period. These data suggest that FO-mediated decreases
in sd-LDL concentrations may reflect decreases in apo B
and VLDL concentrations. A limitation of our study is
that we didn’t analyze the discrimination of HDL2/
HDL3-subclasses. Previous report suggested that LDL
size and density are inversely correlated with plasma
concentrations of HDLs, particularly those of the HDL2
subclass [31]. Therefore, it is necessary to analyze the
discrimination of HDL2/HDL3-subclasses for further
study.
This study has shown that FO supplementation mark-
edly decreases serum sd-LDL concentrations, particu-
larly in subjects with TG concentrations of >100 mg/dl.
In conclusion, this study indicates that the FO, which is
a rich source of ALA, leads to lower sd-LDL cholesterol
concentrations.
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